BAT Launches Virtual R&D Visitor Experience

Apr.07.2022
BAT Launches Virtual R&D Visitor Experience
BAT launches virtual visitor experience showcasing cutting-edge research and development activities in various scientific fields.

January 19, 2022

 

BAT has launched a new virtual visitor experience that allows guests to "walk through" the company's research and development laboratories, meet top scientists, and view the results of new research. Tourists have the opportunity to explore the company's scientific methods and progress in reducing tobacco harm, as well as showcasing R&D activities in important and emerging fields such as biology, chemistry, toxicology, sensory science, aerosol analysis, product safety, consumer insights, and plant biotechnology. This underscores BAT's commitment to science in reducing the impact of its business on health and providing a better tomorrow. TMBAT has created a virtual R&D visitor experience, an online tour of its global R&D center located in Southampton, UK, allowing people to explore its cutting-edge science and innovation.

 

Experience is built on a foundation of the best available technology, open and transparent scientific methods, which support the reduction of risk in product portfolios and beyond nicotine activities. The company regularly welcomes visitors to its global research center, with over 3,500 people seeing the facilities firsthand since 2011. However, with travel greatly reduced, virtual experiences allow people from around the world to access and understand BAT's scientific research, reduce tobacco harm reduction (THR) activities, and gain insights and perspectives from experts.

 

David O'Reilly, PhD, the Director of scientific research at BAT, emphasized the importance of research and development as the foundation of their work. By prioritizing science and research, they have made significant progress in developing new product categories that have undergone rigorous testing and scientific validation as reduced-risk alternatives to traditional tobacco products. Their research is heavily influenced by consumer preferences and continually incorporates evolving scientific and innovative developments into their products. This approach allows them to offer a range of enjoyable, reduced-risk alternatives to cigarettes while maintaining very high safety and quality standards.

 

Our new virtual visitor experience showcases the breadth of science we are conducting and the strong scientific framework we are using to evaluate and support our products in reducing tobacco harm.

 

A virtual visitor experience has been developed, offering a one-stop center for people who wish to learn about the science behind BAT. This includes a tour through the 360-degree lab, animations, videos, scientist profiles and podcasts. The aim of this initiative is to highlight BAT's commitment in building a better future while reducing its impact on public health. BAT invests nearly £350 million annually to find innovative ways to reduce its influence on public health and aims to have 50 million non-combustible product consumers by 2030.

 

BAT conducts research in a wide range of scientific fields including molecular biology, toxicology, and chemistry, driving constant innovation and learning, and establishing the company as an industry leader.

 

Visitors who take a tour of the research and development virtual experience will be able to explore:

 

Sensory Science: This specialized department helps BAT better understand consumer product experiences and decodes them into actionable insights to support product and brand development. Biotech Laboratory: BAT scientists utilize their specialized knowledge in whole-genome sequencing, metabolomics, and computational biology to provide enhanced consumer experiences. These teams also grow plants and identify sustainable compound sources. Biology Laboratory: Scientists test BAT's new category products for potential impacts on human cells compared to cigarette smoke. Battery Laboratory: The facility revolutionizes the design, development, and testing of BAT's rechargeable devices. The batteries undergo rigorous speed tests to ensure they meet high-quality standards.

 

Original link:

 

British American Tobacco (BAT) has launched a virtual research and development visitor experience, showcasing world-class science behind their next-generation reduced-risk† nicotine products.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland has increased tobacco excise under Budget 2027 and announced a further rise in its E-liquid Products Tax. From Oct. 7, the tax burden on a pack of 20 cigarettes in the most popular price category increased by €1, with pro-rata increases on other tobacco products. The government plans to raise EPT from €0.50 to €0.70 per millilitre from Jan. 1, 2027, a 40% increase applying to both nicotine-containing and nicotine-free e-liquids. The tobacco duty increase is expected to raise about €63.1 million in a full year.
Regulations
Oct.09
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Four CrossBar 20K disposable e-cigarettes appeared on Pennsylvania's 163-entry ENDS directory ahead of enforcement beginning October 19, 2026. The devices feature 13mL e-liquid reservoirs, 50mg/mL nicotine, 2,000mAh batteries and 0.9Ω mesh coils, with advertised puff counts of up to 20,000. CrossBar was the only modern high-puff disposable series among the directory's 15 disposable entries. Its packaging emphasizes New York design and Japanese-origin flavoring, while historical CrossBar records identify a registered U.S. tobacco manufacturing-related establishment. The link between the newer 13mL devices and earlier 1.3mL PMTA filings remains unconfirmed.
product
Oct.26
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Pennsylvania began enforcing its electronic nicotine delivery system directory restrictions on October 19, 2026. Among 163 product listings recorded before enforcement, four CrossBar 20K disposables stood out with 13mL capacity, advertised puff counts of up to 20,000 and a flattened design distinct from conventional pod systems and compact disposables. Historical records identify earlier 1.3mL CrossBar products associated with Romo LLC, while newer 13mL products appeared in several state directories beginning in 2025 under entities including Blue Nine LLC. PMTA compliance expert Mr. K identified amendments and application ownership transfers as possible regulatory mechanisms, although neither has been confirmed in this case. Separately, Reynolds' $7.5 million acquisition of 16 PACHA products and related assets illustrates the commercial value of products linked to historic PMTA submissions.
Special Report
Oct.22
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore and four authorized U.S. CCELL distributors are asking a California federal court to permanently dismiss a core antitrust claim brought by direct purchasers. Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on price competition among distributors, amounting to a per se unlawful horizontal conspiracy. The defendants say the alleged conduct reflects ordinary vertical relationships between a manufacturer and its distributors. The court previously dismissed a similar claim, and the latest dispute centers on whether the second amended complaint adds sufficient facts to establish a horizontal agreement.
Sep.14